Business
Neuronetics® Hits Major Milestones with More Than 2.5 Million Treatments and 1,000 Installations of Its NeuroStar® Advanced Therapy System
An increasing number of patients and providers are turning to the transcranial magnetic stimulation (TMS) market leader as a proven, non-drug treatment option
About this update from Neuronetics, Inc.
[{"type":"text","content":"An increasing number of patients and providers are turning to the transcranial magnetic stimulation (TMS) market leader as a proven, non-drug treatment option for depression\nMALVERN, Pa., March 16, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced it has delivered over 2.5 million treatments with its NeuroStar® Advanced Therapy transcranial magnetic stimulation (TMS) system, in addition to recently exceeding 1,000 device installations in the United States. These important milestones further demonstrate NeuroStar as a much-needed, non-drug treatment option for adults with Major Depressive Disorder (MDD) that is helping to tackle the country’s critical depression issue.\n Depression impacts more than 13.3 million adults in the U.S., but many do not seek treatment1,2,3 — resulting in a need for accessible, safe, non-drug treatment options that work. Unlike electroconvulsive therapy (ECT), NeuroStar TMS is a non-drug, non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that are underactive in depression.4,5 Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar has become a trailblazer in the treatment of depression and is the number one TMS choice of doctors. Now with over 2.5 million NeuroStar treatments delivered and over 1,000 devices installed across the U.S., NeuroStar is available in nearly every state. “These milestones indicate that doctors continue to trust NeuroStar as the number one TMS choice in the country and, as a result, more men and women with depression are getting access to this non-drug treatment that has the potential to be life-changing,” said Dan Guthrie, Chief Commercial Officer of Neuronetics, Inc. “We are so proud of how far we’ve come over the last decade, but we know there’s still work to do. We remain committed to transforming lives and ensuring that as many people as possible not only know about NeuroStar as a treatment option, but also have access to it.” “After struggling with depression for nearly 20 years, and finding no relief with antidepressants, my doctor and I decided on NeuroStar as my next step, and...